A Phase 2 interventional study of Finasteride 23.5 mg tablets and Finasteride 33.5 mg tablets in NODULOCYSTIC ACNE, sponsored by Elorac, Inc.. Completed at 25 sites in United States. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Elorac, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 162nd largest by enrollment of the 353 interventional ones that give a count, is one of 25 that started in 2015, is one of 65 in phase 2, and was the 170th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
Sagimet Biosciences Inc. · Sites in United States, Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 35 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 25 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 353 interventional studies, 59 across the 19 observational. Of the 322 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 373 have an industry lead sponsor. The 10 most frequent:
Elorac, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Elorac, Inc. has 1 study filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
9 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 373 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of once weekly, high dose oral finasteride compared to placebo for the treatment of severe nodulocystic acne in male subjects.
There will be 180 male subjects in this study. The study is composed of a Screening Period of up to 30 days during which inclusion / exclusion criteria will be reviewed, screening laboratory results will be obtained and medication washouts will be done as required. Subjects will complete the sexual function questionnaire and depression scale. A one day Baseline Period (Day 0), during which baseline assessments of acne lesion counts, physical examination and Investigator's Global Assessment Scale will be done. The Baseline Period will be followed by a 12-week randomized double-blind Treatment Period, in which subjects will be randomized into Finasteride 23.5 mg group, 33.5 mg group, or placebo group. During the Treatment Period, subjects will visit the study site Day 14, Day 28, and Day 56 for acne lesion counts and review of diaries, concomitant medications and adverse events. On Day 84 subjects will return to clinic for acne lesion counts and review of diaries, concomitant medications, adverse events and remaining study drug will be counted and collected. A physical exam and vital signs, Investigator Global Assessment, Subject Assessment of Efficacy, depression scale and sexual function questionnaire will be completed before the subject is discharged from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Finasteride 23.5mg tablets and large placebo tablets once per week
Drug: Finasteride 23.5 mg tablets · Drug: Placebo tablets
Finasteride 33.5 mg tablets and small placebo tablets once per week
Drug: Finasteride 33.5 mg tablets · Drug: Placebo tablets
Large and small placebo tablets once per week
Drug: Placebo tablets
Acne Nodular Lesion Count
Change from Baseline to week 12 in the total number of nodular lesions
Time frame: 12 Weeks
Proportion of Subjects who achieve at least a 75% reduction in total number of nodular lesions
Change from Baseline to week 12 in the total number of nodular lesions
Time frame: 12 Weeks
Investigator's Global Assessment Scale of Acne Severity
Change from Baseline to week 12
Time frame: 12 Weeks
Non-Inferiority (NI) for non-nodulocystic inflammatory lesions
The NI bound will be larger of 10% reduction or a count of 4 lesions.
Time frame: 12 Weeks
Change in total number of nodular lesions.
Change from baseline to weeks 2, 4 and 8.
Time frame: 2, 4, and 8 weeks
Proportion of subjects with 2 category improvement on Investigator's Global Assessment Scale
Change from Baseline to week 12
Time frame: 12 Weeks
The record gives a start of Jul 2015, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finasteride